Core Viewpoint - MindWalk has launched an innovative dual-pathway treatment plan targeting aging and longevity, expanding its AI-driven GLP-1 therapy project, which combines an AI-optimized GLP-1 receptor agonist with a proprietary auxiliary drug, marking a first in the industry with no similar products currently available in the market [4][7]. Group 1: Treatment Plan Overview - The primary pathway involves an AI-optimized long-acting GLP-1 receptor agonist, designed from scratch using the LensAI platform, showing comparable or superior receptor activation in preclinical experiments compared to semaglutide [7]. - The auxiliary pathway focuses on a "longevity/resilience" mechanism, with specific targets currently undisclosed, and has been developed using the HYFT fingerprint engine and LensAI, with a temporary patent already submitted [9]. - The combination of these two drugs is planned to be packaged as a "fixed-dose long-acting formulation," with ongoing preclinical studies in animal models to validate dosage and administration intervals [9]. Group 2: Platform and Technology - The entire treatment plan is driven by the Bio-Native AI platform, which has already supported over 15 candidate projects into clinical development, emphasizing that AI's role extends beyond molecular optimization to discovering pathways before drug design [9]. - The LensAI platform, supported by the HYFT discovery engine, has identified conserved biological patterns related to GLP-1 signaling and longevity biology, facilitating the discovery of new biological mechanisms [5][9]. - The integration of these technologies allows for a closed-loop process of design, construction, testing, and learning, which has successfully led to the development of multiple therapeutic candidates [5].